{"type":"trials","record":{"id":87193,"source_id":"isrctn","external_id":"ISRCTN01449944","title":"A non-controlled trial of anti-Tumour Necrotising Factor alpha (anti-TNFa) chimeric monoclonal antibody (Infliximab, Remicade®) in exudative age-related macular degeneration","brief_summary":"Treatment with Infliximab will reduce loss of visual acuity by 8 letters or better on the ETDRS chart.","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"Erasmus Medical Centre (The Netherlands)","enrollment":13,"countries":["Netherlands"],"start_date":"2006-01-01","completion_date":"2007-12-31","last_update_date":"2021-10-28","source_url":"https://www.isrctn.com/ISRCTN01449944","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN01449944; retrieved 2026-09-25","interventions":["Infliximab, Remicade®","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Absolute change in Visual Acuity (VA) versus baseline of the target eye. Target eye for primary endpoint is defined as…","1. Proportional changes in VA using ETDRS chart, measured at baseline, weeks 2, 6, 14, 22, 30, 38, 46, 52 and 72 2. Pro…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Exudative age-related macular degeneration","Infliximab (5 mg/kg) in saline solution (0.9%) at weeks 0, 2, 6, 14, 22, 30, 38 and 46.","Infliximab, Remicade®","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn01449944","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2006-01-01 to 2007-12-31","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.598Z","intervention":["Infliximab, Remicade®","Drug"],"participants":13,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Absolute change in Visual Acuity (VA) versus baseline of the target eye. Target eye for primary endpoint is defined as…","1. Proportional changes in VA using ETDRS chart, measured at baseline, weeks 2, 6, 14, 22, 30, 38, 46, 52 and 72 2. Pro…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87193","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}